You are the Key to HPV Cancer Prevention

Janel Johnson, DO MPH
Cherokee Nation Health Services
Wilma P. Mankiller Health Center Stilwell, OK



Disclosure Statement

■ I have no disclosures to make.



Objectives

- 1. Describe why HPV vaccination is important for cancer prevention.
- 2. Identify the appropriate HPV vaccination schedule based on patient age.
- 3. Describe effective HPV vaccine recommendations for patients age 11 or 12 years, as well as for age 13 years and older.
- 4. Develop self-efficacy in delivering effective HPV vaccination recommendations
- Identify reassuring, confident, and concise responses to parental questions about HPV vaccination.
- 6. Implement disease detection and prevention health care services (e.g., smoking cessation, weight reduction, diabetes screening, blood pressure screening, immunization services) to prevent health problems and maintain health. (REQUIRED FOR PHARMACY CREDIT)






Understanding the Burden

HPV INFECTION & DISEASE



HPV Types Differ in Their Disease Associations





HPV Infection

- Most females and males will be infected with at least one type of mucosal HPV at some point in their lives
 - Estimated 79 million Americans currently infected
 - 14 million new infections/year in the US
 - HPV infection is most common in people in their teens and early 20s
- Most people will never know that they have been infected




Cancers Caused by HPV per Year, U.S., 2011–2015

Cancer site	Percentage probably caused by any HPV type	Number probably caused by any HPV type		
		Female	Male	Both Sexes
Cervix	91%	10,800	0	10,800
Vagina	75%	600	0	600
Vulva	69%	2,700	0	2,700
Penis	63%	0	800	800
Anus*	91%	4,000	1,900	5,900
Oropharynx	70%	2,200	10,700	12,900
TOTAL		20,300	13,400	33,700



^{*}Includes anal and rectal squamous cell carcinomas Sources: https://www.cdc.gov/cancer/hpv/statistics and Saraiya M et al. J Natl Cancer Inst. 2015;107:djv086

Number of HPV-associated and HPV-attributable cancer cases per year, United States, 2011-2015




^b Includes anal and rectal squamous cell carcinomas

For each cancer type, we estimated HPV-attributable cancers by multiplying the number of cancer cases by the percentage attributable to HPV based on a genotyping study. We estimated that 33,700 cancers (79%) were attributable to HPV each year during 2011–2015. Of these, we estimated that 31,200 cancers could have been prevented by the 9-valent HPV vaccine, including 27,100 caused by HPV types 16 and 18, and 4,100 caused by HPV types 31/33/45/52/58. HPV-negative cancers are not shown in the graph; it is estimated that about 10% of cervical and anal cancers, 30% of oropharyngeal, vaginal, and vulva cancers and 40% of penile cancers are HPV-negative.




HPV-Associated Cancer Rates by Sex, Race, and Ethnicity, United States, 2011–2015






HPV-Associated Anal* Cancer Rates by Sex, Race, and Ethnicity, United States, 2011–2015






HPV-Associated Oropharyngeal Cancer Rates by Sex, Race, and Ethnicity, United States, 2011–2015






HPV-Associated Penile Cancer Rates by Race, and Ethnicity, United States, 2011–2015






HPV-Associated Vaginal Cancer Rates by Race, and Ethnicity, United States, 2011–2015






HPV-Associated Vulvar Cancer Rates by Race, and Ethnicity, United States, 2011–2015






HPV-Associated Cervical Cancer Rates by Race, and Ethnicity, United States, 2011–2015





Cervical Cancer

- Cervical cancer is the most common HPV-associated cancer among women
 - 528,000 new cases and 266,000 deaths worldwide in 2012
 - In 2015 approx. 12,800 new cases and 4,000 deaths in the U.S.




- Half of cervical cancers occur in women <50 years</p>
 - A quarter of cervical cancers occur in women 25-39 years




Cervical Pre-Cancer in U.S. Females

→ ~300,000 high grade cervical lesions every year








Evidence-Based HPV Disease Prevention

HPV VACCINE



HPV Prophylactic Vaccines

- Recombinant L1 capsid proteins that form "virus-like" particles (VLP)
- Non-infectious and non-oncogenic
- Produce higher levels of neutralizing antibody than natural infection




HPV Virus-Like Particle



HPV Vaccine Comparison

HPV Types Included in Vaccine



HPV Vaccine Recommendation

CDC recommends routine vaccination at age 11 or 12 years to prevent HPV cancers

- The vaccination series can be started at age 9 years.
- 2 doses of vaccine are recommended.
- The second dose of the vaccine should be administered 6 to 12 months after the first dose.



HPV Vaccine Recommendations: Catch-Up/Late

- Vaccination for females through age 26 years and for males through age 21 years who were not previously adequately vaccinated. Males aged 22 through 26 years may be vaccinated.
- Vaccination is also recommended through age 26 for gay, bisexual, and other men who have sex with men (MSM), transgender people, and people with certain immunocompromising conditions (including HIV infection).



Dosing Schedules

Starting the vaccine series before the 15th birthday

Recommended schedule is 2 doses of HPV vaccine

- Second dose should be administered 6–12 months after the first dose (0, 6–12 month schedule)
- Minimum interval between dose 1 and dose 2 in a2-dose schedule is 5 months

Starting the vaccine series on or after the 15th birthday*

Recommended schedule is 3 doses of HPV vaccine

- Second dose should be administered 1–2 months after the first dose, and the third dose should be administered 6 months after the first dose (0, 1–2, 6 month schedule)
- Minimum interval between dose one and dose three in a 3-dose schedule is 5 months

^{*}And immunocompromised persons 9-26 years



HPV Vaccine Administration

- Administer HPV vaccines via intramuscular (IM) injection
 - Needle size: 1- to 1½- inch, 22- to 25-gauge
 - Site: Deltoid muscle in the upper arm
- Follow proper injection practices
 - Use aseptic technique
 - Use a new needle and syringe for each injection
- Administer at the same medical visit as other adolescent vaccines



HPV Vaccine Storage and Handling

Store HPV vaccine in a refrigerator between2°C - 8°C (36°F - 46°F)

Store HPV vaccines:

- In the original packaging with the lids closed
- In a clearly labeled bin and/or area of the storage unit

Do not freeze the vaccine

9vHPV (Gardasil 9)

Administer to females and males

Use for: 9 years through 26 years

Recommended ages: 11 years or 12 years


Catch-up ages: 13 years through 26 years

Route: Intramuscular (IM) injection



PREVENTING CANCER JUST GOT EASIER

HPV vaccine protects against cancers and other diseases caused by human papillomavirus (HPV). Follow the chart below to determine whether your patient needs two or three doses of HPV vaccine.



CDC RECOMMENDS TWO HPV DOSES FOR YOUNGER ADOLESCENTS

The Centers for Disease Control and Prevention (CDC) now routinely recommends two doses of HPV vaccine for 11- or 12-year-olds to prevent HPV cancers. This recommendation makes it easier for parents to protect their children by reducing the number of doses and trips to the doctor. HPV vaccination is an important cancer prevention tool and two doses of HPV vaccine will provide safe, effective, and long-lasting protection. Some specifics of the recommendation include:

- A two-dose schedule is recommended for adolescents starting the schedule at ages 9 through 14 years. For this age group, follow the decision tree on the reverse side.
- Adolescents aged 9 through 14 years who have already received two doses of HPV vaccine less

than 5 months apart will require a third dose. The third dose should be given 6–12 months after the first dose to complete the series.

- A three-dose schedule is recommended for teens and young adults who start the series at ages 15 through 26 years. Under this schedule, the second dose of HPV vaccine should be given 1–2 months after the first dose, and the third dose should be given 6 months after the first dose.
- Three doses are recommended for people aged 9–26 years with certain immunocompromising conditions.

Read the full policy note: www.cdc.gov/mmwr/volumes/65/wr/mm6549a5.htm

TALKING TO PATIENTS AND THEIR PARENTS ABOUT 2-DOSE SCHEDULES FOR HPV VACCINATION

With patients aged 11–12 years, start the vaccine discussion with their parents by making the following recommendation: "Now that your child is 11 (or 12) years old, they are due for three vaccines today to help protect them from the infections that cause meningitis, HPV cancers, and pertussis—or whooping cough."

Many parents are accepting of this bundled recommendation because it demonstrates that HPV vaccination is a normal part of adolescent vaccination. Parents may be interested in vaccinating, yet still have questions. Some parents might just need additional information from you, the clinician they trust. Clarify the parent's question or what additional information they need.

For parents who have a question or need more information about "why now/why 11–12?"

"As with all vaccine-preventable diseases, we want to protect your child early. If we start now, it's one less thing for you to worry about. Also, your child will only need two doses of HPV vaccine at this age. If you wait, your child may need three doses in order to get complete protection. We'll give the first dose today and then you'll need to bring your child back in 6 to 12 months from now for the second dose."

If a parent asks, or needs more information about "How long can we wait and still give just two doses?"

"The two-dose schedule is recommended if the series is started before the 15th birthday. However, I don't recommend waiting to give this cancer-preventing vaccine. As children get older and have busier schedules, it becomes more difficult to get them back in. I'd feel best if we started the series today to get your child protected as soon as possible."

For patients aged 9–14 who have already had two doses given less than 5 months apart

"The recommended schedule is two doses given 6 to 12 months apart. The minimum amount of time between those doses is 5 months. Because your child received two doses less than 5 months apart, we'll need to give your child a third dose."

For parents asking about the duration of protection or how well the vaccine will work with just two doses

"Studies have shown that two doses of HPV vaccine work very well in younger adolescents and we expect the same long-lasting protection with two doses that we expect with three doses." You can also access guidance on answering parents' questions about HPV vaccine by using our tip sheet, Talking to Parents about HPV Vaccine, at www.cdc.gov/HPV.





MARCH 2017



HPV Vaccination Is Recommended at Age 11 or 12 Years

Girls & Boys can start HPV vaccination at age 9

Preteens should finish the HPV vaccine

series before their 13th birthday




Plus girls 13-26 years old who haven't started or finished HPV vaccine series



Plus boys 13-21 years old who haven't started or finished HPV vaccine series





HPV VACCINE SAFETY



United States Vaccine Safety System

System	Collaborators	Description
Vaccine Adverse Event Reporting System (VAERS)	CDC and FDA	Frontline, spontaneous reporting system to detect potential vaccine safety issues
Vaccine Safety Datalink (VSD)	CDC and 8 integrated health care systems	Large-linked database system used for active surveillance and research ~9.4 million members (~3% of US pop)
Clinical Immunization Safety Assessment (CISA) Project	CDC and 7 academic centers	Expert collaboration that conducts individual clinical vaccine safety assessments and clinical research
Post-Licensure Rapid Immunization Safety Monitoring Program (PRISM)	•	Large distributed database system used for active surveillance and research ~170 million individuals (~53 of US pop)



Over 10 Years of HPV Vaccine Safety Data

- HPV vaccines are safe
- Reactions after vaccination may include:
 - Injection site reactions: pain, redness, and/or swelling in the arm where the shot was given
 - Systemic: fever, headaches
- HPV vaccines should not be given to anyone who has had a previous allergic reaction to the HPV vaccine or who has an allergy to yeast
- Brief fainting spells (syncope) and related symptoms (such as jerking movements) can happen soon after any injection, including HPV vaccine
- Patients should be seated (or lying down) during vaccination and remain in that position for 15 minutes

Evaluating and Monitoring 9-Valent HPV Vaccine Safety in the United States

Monitoring of VAERS reports

- Clinical review of serious reports including deaths and other prespecified adverse events
- Data mining to identify disproportional reporting

Vaccine Safety Datalink

- Near real-time monitoring of 10 prespecified outcomes
- Evaluation of spontaneous abortion

Sentinel System

- Active surveillance and surveillance of serious, unexpected events
- Evaluation of spontaneous abortion

Manufacturer postmarketing commitments

- Two 10-year studies to assess long-term safety
- Observational study to further characterize the safety profile in 10,000 persons
- Pregnancy registry




HPV Vaccination Is Safe

HPV vaccine safety studies have been very reassuring: HPV vaccine has a good safety profile.

CDC and FDA continue to monitor and evaluate the safety of HPV vaccines, along with all vaccines.

Clinicians can reassure parents who may have concerns that HPV vaccination is safe.





Monitoring Impact of HPV Vaccine Programs on HPV-Associated Outcomes

HPV VACCINE IMPACT



HPV Vaccine Impact Monitoring

- Postlicensure evaluations are important to evaluate real-world effectiveness of vaccines
- Population impact against early and mid outcomes has been reported in many countries, including:

HPV prevalence

Australia, Norway, Denmark, Sweden, Switzerland, UK, U.S.

Genital warts

 Australia, Belgium, New Zealand, Denmark, Sweden, Germany, Quebec, U.S.

Cervical lesions

Australia, British Columbia, Denmark, Scotland, Sweden, U.S.



HPV Vaccine Impact in the U.S.


Declines observed in:

- Vaccine type prevalence
- Genital warts
- Cervical precancers




Vaccine Type Prevalence Among Females, NHANES

Early vaccine era compared to pre-vaccine era






Vaccine Type Prevalence Among Females, NHANES Later vaccine era compared to pre-vaccine era





Impact of HPV Vaccination in Australia

Proportion of Australian-born females and males diagnosed as having genital warts at first visit, by age group, 2004-11





Systematic Review and Meta-Analysis: Population-Level Impact of HPV Vaccination

- Review of 20 studies in 9 high-income countries
- In countries with >50% coverage, among 13-19 year-olds
 - HPV 16/18 prevalence decreased at least 68%
 - Anogenital warts decreased by ~61%
- Evidence of herd effects
- Some evidence of cross protection against other types



HPV Vaccine Duration of Protection

- Studies suggest that vaccine protection is long-lasting
- **■** No evidence of waning protection
 - Available evidence indicates protection for at least 10 years
 - Multiple studies are in progress to monitor



HPV Vaccination Is Safe, Effective, and Provides Lasting Protection

HPV Vaccine Is SAFE

- Benefits far outweigh any potential risks
- Safety studies findings for HPV vaccination are reassuring and similar to MenACWY and Tdap vaccine safety reviews


HPV Vaccine WORKS

 Population impact against early and mid outcomes has been reported in multiple countries

HPV Vaccine Protection LASTS

- Studies suggest that vaccine protection is long-lasting
- No evidence of waning protection






Talking About HPV Vaccine

FRAMING THE CONVERSATION




Adolescent Vaccination Coverage United States, 2006-2017

FIGURE. Estimated coverage with selected vaccines and doses* among adolescents aged 13–17 years, by survey year and ACIP recommendations† — National Immunization Survey-Teen, United States, 2006–2017§



Abbreviations: ACIP = Advisory Committee on Immunization Practices; HPV = human papillomavirus; MenACWY = quadrivalent meningococcal conjugate vaccine; Tdap = tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine; UTD = up to date.

in recommendation, the graph includes estimates for ≥3 doses HPV from 2011 to 2015 and the HPV UTD estimate for 2016 and 2017. Because HPV vaccination was recommended for boys in 2011, coverage for all adolescents was not measured before that year.






^{* ≥1} dose Tdap at or after age 10 years; ≥1 dose MenACWY or meningococcal-unknown type vaccine; ≥2 doses MenACWY or meningococcal-unknown type vaccine, calculated only among adolescents aged 17 years at time of interview. Does not include adolescents who received their first and only dose of MenACWY at or after 16 years of age; HPV vaccine, nine-valent (9vHPV), quadrivalent (4vHPV). The routine ACIP recommendation for HPV vaccination was made for females in 2006 and for males in 2011. Because HPV vaccination was not recommended for males until 2011, coverage for all adolescents was not measured before that year; HPV UTD includes those with ≥3 doses and those with 2 doses when the first HPV vaccine dose was initiated before age 15 years and at least 5 months minus 4 days elapsed between the first and second dose.


[†] ACIP revised the recommended HPV vaccination schedule in late 2016. The recommendation changed from a 3-dose to 2-dose series with appropriate spacing between receipt of the first and second dose for immunocompetent adolescents initiating the series before the 15th birthday. Three doses are still recommended for adolescents initiating the series between the ages of 15 and 26 years. Because of the change

Impact of Eliminating Missed Opportunities by Age 13 Years in Girls Born in 2000






Parents of unvaccinated girls – top reasons for not starting HPV vaccine series






Value Parents Place on the Vaccines






Clinician Estimations





Clinicians Underestimate the Value Parents Place on HPV Vaccine





"The perceived and real concerns of parents influence how clinicians recommend HPV vaccine."



Give an Effective Recommendation to Receive HPV Vaccine at Age 11 or 12

- An effective recommendation from you is the main reason parents decide to vaccinate
- Many moms in focus groups stated that they trust their child's clinician and would get the vaccine for their child as long as they received a recommendation from the clinician



What is an EFFECTIVE recommendation for HPV vaccination?



Same Way Same Day




Make an Effective Recommendation

- Same way: Effective recommendations group all of the adolescent vaccines
 Recommend HPV vaccination the same way you recommend Tdap and meningococcal vaccines
- Same day: Recommend HPV vaccine *TODAY*Recommend HPV vaccination the same day you recommend Tdap and meningococcal vaccines



Your preteen needs three vaccines today to protect against meningitis, HPV cancers, and pertussis.









Now that Sophia is 11, she is due for three vaccines.

These will help protect her from the infections that can cause meningitis, HPV cancers, and pertussis.

We'll give those shots today.



Now that Sophia is 11, she is due today for three important vaccines.

The first is to help prevent an infection that can cause meningitis, which is very rare, but potentially deadly. The second is to prevent a very common infection, HPV, that can cause several kinds of cancer. The third is the tetanus booster which also protects against pertussis, so she doesn't get whooping cough.

We'll give those shots at the end of the visit. Do you have any questions for me?

Some Parents Need Reassurance

- Many parents simply accept this bundled recommendation
- Some parents may be interested in vaccinating, yet still have questions. Interpret a question as they need additional reassurance from YOU, the clinician they trust with their child's health care
- Ask parents about their main concern
 (be sure you are addressing their real concern)



Why does my child need HPV vaccine?





HPV vaccination is important because it prevents cancer.

That's why I'm recommending that your child start the HPV vaccine series today.



What cancers are caused by HPV infection?





Persistent HPV infection can cause cancer of the cervix, vagina, and vulva in females, cancer of the penis in males, and cancers of the anus and the throat in both.

We can help prevent infection with the HPV types that cause these cancers by starting the HPV vaccine series today.



Is my child really at risk for HPV?





HPV is a very common virus that infects both females and males.

We can help protect your child from the cancers and diseases caused by the virus by starting HPV vaccination today.

Why at 11 or 12 years old?



When should the bike helmet go on?



- A. Before they get on their bike
- B. When they are riding their bike in the street
- C. When they see the car heading directly at them
- D. After the car hits them



When do we put our seat belts on?

A. Before turning on car

B. When leaving driveway

C. After a near accident





As with all vaccine-preventable diseases, we want to protect your child early. If we start now, it's one less thing for you to worry about.

Also, your child will only need 2 shots of HPV vaccine at this age. If you wait until 15, your child will need three shots.

We'll give the first shot today and then you'll bring your child back in 6 to 12 months for the second shot.

I'm just worried that my child will perceive this as a green light to have S-E-X.



Numerous research studies have shown that getting the HPV vaccine does NOT make kids more likely to be sexually active or start having sex at a younger age.

Starting the HPV vaccine series today will give your child the best possible protection for the future.

How long can we wait and still give just two doses?





The two-dose schedule is recommended if the series is started before the 15th birthday.

However, I don't recommend waiting to give this cancer-preventing vaccine. Older teens have busier schedules and it becomes more difficult to schedule an appointment.

It's best to start the series today so your child is protected as soon as possible.

I'm concerned about the safety of the vaccine—I read things online that say HPV vaccine isn't safe.

Do you really know if it's safe?



It sounds like you want what's best for your child and have concerns about the safety of HPV vaccine. Is that right?

We both want what's best for your child. Can you tell more about your concerns?

I have researched HPV vaccine including safety. Can I share with you what I have learned?



I know there are stories in both the media and online about vaccines. However, I want you to know that HPV vaccine has been carefully studied for many years by medical and scientific experts.

Based on all these studies, I believe HPV vaccine is very safe.



Vaccines, like any medication, can cause side effects. With HPV vaccination, this could include pain, swelling, and/or redness where the shot is given, or possibly a headache.

No serious side effects have been associated with HPV vaccine.



Can HPV vaccine cause future fertility problems?



There is no evidence available to suggest that HPV vaccine will affect future fertility. However, women who develop cervical cancer could require treatment that would limit their ability to have children.

Starting the HPV vaccine series today could prevent that from happening and protect your daughter's ability to bear children.



How do you know if the vaccine works?



Ongoing studies continue to show that HPV vaccination works very well. HPV infections, genital warts, and cervical precancers in young people have all decreased in the years since the vaccine has been available. Starting the vaccine series today will help ensure your child gets the best protection possible.

Why do boys need to be vaccinated?





HPV infection can cause cancers of the penis, anus, and throat in men.

HPV infection can also cause genital warts.

Getting HPV vaccine today for your son can help prevent the infection that can lead to these diseases.

We only want the vaccines needed for school.





School-entry requirements don't always reflect the current recommendations to keep your child healthy.

HPV vaccine, along with other adolescent vaccines, will provide your child with the best protection.

Would you give HPV vaccine to your kids?





Yes, I have given HPV vaccine to my child.

I believe strongly in the importance of this cancer-preventing vaccine.

Also, the American Academy of Pediatrics, the American Academy of Family Physicians, NIH cancer centers, and CDC agree that HPV vaccination is very important for your child.



I heard there is a new HPV vaccine that works better. Should I be getting that for my child who already was vaccinated?





Currently there is no recommendation for additional vaccination for someone who has already completed an HPV vaccine series.

All HPV vaccines protect against the infections that cause most of the cancers.



When do we need to come back?





Since your child is younger than 15, she will need a second shot in 6 months to a year.

When you check out, please make sure to make an appointment for the second shot and put that appointment on your calendar before you leave today!





Since your child is already 15, she will need a second shot in 1-2 months. The third shot is due 6 months from today.

When you check out, please make sure to make an appointment for about 1-2 months from now and 6 months from now, and put those appointments on your calendar before you leave today!

My child is less than 15 years old, so why does she need a third shot?





The recommended schedule is 2 shots given 6 to 12 months apart.

The minimum amount of time between those shots is five months.

Because your child received two shots *less* than five months apart, we'll need to give your child a third shot.

Will my child be protected with just two shots?





Yes! Studies have shown that just two shots given at least six months apart, when the first dose is given between 9 and 14 years, worked as well or better than three shots given to older adolescents and young adults.



If a Parent Doesn't Say Yes Today...

Ask	Clarify and restate their concerns to make sure you understand
Acknowledge	 Emphasize it is the parents' decision Acknowledge risks and conflicting info sources Applaud them for wanting what is best for their child Be clear that you are concerned for the health of their child—not just public health safety
Advise	 Allow time to discuss the pros and cons of the vaccine Be willing to discuss parents' ideas Offer written resources for parents Tailor your advice using this presentation



If a Parent <u>Declines Today</u>

- Declination is not final. The conversation can be revisited
- End the conversation with at least one action you both agree on
- Because waiting to vaccinate is the risky choice, many pediatricians ask the parent to sign a declination form



Ensure ALL Your Patients are Protected

- Align office/clinic policy with mission
 - Immunize at every opportunity
 - Implement and utilize standing orders
 - Prompt the clinician to assess and administer the vaccine
 - EMRs, IIS, etc.
 - Reminder and recall





SEARCH

Q

CDC A-Z INDEX >

Human Papillomavirus (HPV)

HPV Home For Parents & Public For Clinicians Why is HPV Vaccine Important Clinician Factsheets Schedules &

Recommendations Answering Parents Questions

HPV Coverage Data

Materials & Resources Speaking to Colleagues

HPV Vaccine Champions Award

How I Recommend Videos

For Partners & Programs

Related Links

Immunization Partners

Sexually Transmitted

Diseases

HPV-Associated Cancers

Gynecologic Cancers

CDC > HPV Home

For Clinicians

f 💆 🛨





ROUTINELY RECOMMEND **CANCER PREVENTION**

WHY IS HPV VACCINE IMPORTANT?

HPV is so common that almost everyone will be infected with HPV at some point in their lives. Although most HPV infections are asymptomatic, some persistent infections can lead to cancer in both men and women. Hear stories of people who have been affected by HPV and clinicians who take care of them here.

CLINICIAN FACTSHEETS AND GUIDANCE

Discover CDC's resources for clinicians that discuss the burden of HPV disease, HPV vaccine as a primary cancer prevention tool, effective communication with parents, state vaccination rates, and the most recent HPV vaccine recommendations.

SCHEDULES AND RECOMMENDATIONS


Get vaccination schedules to order or print, recommendations to consult, and other helpful tools to download.

ANSWERING THE QUESTIONS PARENTS MAY HAVE

Finding ways to answer parents HPV vaccination questions with straightforward messages based on CDC research with parents.

Keeping All Staff On the Same Page


- Align communication with mission
 - Give staff a cancer-prevention mission
 - All staff need to be saying the same thing
 - Share talking points
 - Use the Tip Sheet
 - Educate staff about HPV vaccine recommendations including schedule, administration, storage and handling





Keeping All Staff On the Same Page

- Multiple education products available free through the CDC website:
 - Immunization courses (webcasts and online self-study)
 - Netconferences
 - You Call the Shots self-study modules
 - Continuing education available





Ensure ALL Your Patients are Protected

- Know your coverage rates— CDC's AFIX can help
- Clinic-level rates are great, but rates for individual clinicians are even better
- Other than coverage assessment and feedback (including AFIX), rates can come from:
 - Data from EHR
 - Immunization Information Systems (IIS) inputs





HPV VACCINE IS CANCER PREVENTION And YOU are the key!

#WeCanStopHPV



References

- Advisory Committee on Immunization Practices. Summary Report. June 22-23, 2016. Available at https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2016-06/june-22-23-2016-acip.pdf
- Ali H, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data BMJ 2013; 346:f2032.
- Baldur-Felskov et al. Trends in the incidence of cervical cancer and severe precancerous lesions in Denmark, 1997-2012. Cancer Causes Control 2015 Aug;26(8):1105-16.
- Benard VB, Castle PE, Jenison SA, et al. Population-Based Incidence Rates of Cervical Intraepithelial Neoplasia in the Human Papillomavirus Vaccine Era. JAMA Oncol. Published online September 29, 2016. doi:10.1001/jamaoncol.2016.3609
- Brewer NT, et al. Announcements versus conversations to improve HPV vaccination coverage: A randomized trial. Pediatrics. 2017 139(1).
- Drolet et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2015 May;15(5):565-80.
- Gee, et al. Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States. Hum Vaccin Immunother. 2016 Jun; 12(6): 1406–1417.
- Hariri S, et al. Population-based trends in high-grade cervical lesions in the early human papillomavirus vaccine era in the United States. Cancer, 121: 2775–2781.
- Healy CM, et al. Parent and provider perspectives on immunization: are providers overestimating parental concerns? Vaccine. 2014; 32(5): 579-584.
- Henrikson NB, et al. A public-private partnership addressing vaccine hesitancy in Washington State. 2014. Available at: http://vaxnorthwest.org/approach
- Institute of Medicine. Adverse Effects of Vaccines: Evidence and Causality. The National Academies Press, 2012.
- Koshiol JE, et al. Rate and predictors of new genital warts claims and genital warts-related healthcare utilization among privately insured patients in the United States. Sex Transm Dis. 2004;31:748–752.
- Machalek et al. Human Papillomavirus Prevalence in Unvaccinated Heterosexual Men After a National Female Vaccination Program. J Infect Dis (2017) 215 (2): 202-208. Published: 03 November 2016. DOI: 10.1093/infdis/jiw530
- Markowitz LE, et al. Prevalence of HPV After Introduction of the Vaccination Program in the United States. Pediatrics. 2016;137(2).
- Meites E, Kempe A, Markowitz LE. Use of a 2-Dose Schedule for Human Papillomavirus Vaccination Updated Recommendations of the Advisory Committee on Immunization Practices. MMWR. 2016;65(49);1405-8.
- Petrosky et al. Use of 9-Valent Human Papillomavirus (HPV) Vaccine: Updated HPV Vaccination Recommendations of the Advisory Committee on Immunization Practices.
 MMWR. 2015 64(11);300-304
- Pollock et al. Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland. Br J Cancer 2014 111, 1824–1830.
- Reagan-Steiner S, et al. National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years United States, 2015. MMWR Morb Mortal Wkly Rep. 2016;65:850–858.
- Satterwhite et al. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008. Sex Transm Dis. 2013 Mar;40(3):187-93.
- Schiffman M. Castle PE. Arch Pathol Lab Med. Human papillomavirus: epidemiology and public health. 2003 Aug;127(8):930-4.
- Smith PJ, et al. HPV vaccination coverage of teen girls: the influence of health care providers. Vaccine. 2016 Mar 18;34(13):1604-10.
- Stokley S,, et al. Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014--United States. MMWR Morb Mortal Wkly Rep. 2014 Jul 25;63(29):620-4.
- Temte JL. Comment: Timing of HPV Vaccine. Available at http://pediatrics.aappublications.org/content/early/2014/08/12/peds.2014-0442.comments#-timing-of-hpv-vaccine-
- Viens LJ. et al. Human papillomavirus—associated cancers—United States. 2008–2012. MMWR. 2016:65:661–6.